Beta-Cell-Mimetic Cells for Autonomous Glycemic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments, particularly for type 1 and type 2 diabetes, face challenges in achieving tight glycemic control and restoring β-cell function, as they often rely on exogenous insulin delivery or have limitations in directly sensing glucose levels and providing real-time therapeutic dosage.
Innovation Solution
Development of β-cell-mimetic cells equipped with a carbohydrate-inducible transcriptional system that senses extracellular carbohydrate concentrations, utilizing a voltage-gated calcium channel to coordinate dose-dependent transcription of therapeutic proteins like insulin and GLP-1, mimicking pancreatic β-cell functions to self-sufficiently manage hyperglycemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous insulin delivery is used to treat diabetes, then insulin deficiency can be compensated, but tight glycemic control and real-time dosage adjustment are difficult to achieve
Solution Approach 1:
The patent creates cells that autonomously sense glucose levels and regulate their own insulin production and secretion without external control. The engineered cells express glucose sensors that trigger insulin gene expression and secretion automatically in response to blood glucose concentrations, eliminating the need for manual dosage adjustment by patients
Solution Approach 2:
The patent implements a feedback mechanism where the engineered cells continuously monitor extracellular glucose levels through expressed glucose sensors and adjust insulin production accordingly. The system uses glucose concentration as a feedback signal to regulate insulin gene expression and secretion, achieving automatic closed-loop glycemic control
2Reliability
If stem cell transplantation is used to restore β-cell function, then glucose-responsive insulin secretion can be restored, but the approach is complex and requires extensive ex vivo reprogramming
Solution Approach 1:
The patent extracts only the essential functions of β-cells (glucose sensing and insulin secretion) and implements them in simpler, non-stem mammalian cells through genetic engineering. Instead of using complex stem cell reprogramming, the invention transfers specific functional elements (glucose sensor expression, insulin gene, secretion machinery) into readily available cell types
Solution Approach 2:
The patent creates a functional copy of β-cell behavior in non-β-cell types by engineering them to express glucose sensors, insulin genes, and secretion mechanisms. The engineered cells copy the essential glucose-responsive insulin secretion function without requiring actual β-cell or stem cell transplantation
3Object-affected harmful factors
If extrapancreatic cell types are engineered to produce insulin, then autoimmune targeting can be avoided, but direct glucose sensing and real-time control remain challenging
Solution Approach 1:
The patent introduces glucose sensor proteins as intermediary molecules that enable extrapancreatic cells to detect extracellular glucose levels. These engineered sensors act as mediators between the external glucose environment and the cell's internal insulin production machinery, allowing non-β-cell types to sense glucose directly
Solution Approach 2:
The patent makes mammalian cells universally capable of glucose sensing and insulin secretion by engineering them with β-cell-like functions. The engineered cells can perform multiple functions: sensing extracellular glucose, transducing the signal, producing insulin in response, and secreting it into the bloodstream, regardless of their original cell type
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The β-cell-mimetic cells effectively correct insulin deficiency, abolish persistent hyperglycemia in type 1 diabetes and improve glucose tolerance in type 2 diabetes by self-regulating insulin and GLP-1 expression in response to glucose levels, offering a promising therapeutic approach for metabolic diseases.
Implementation Method 1
a voltage-gated calcium channel for sensing extracellular carbohydrates
Implementation Method 2
a promoter which is responsive to carbohydrate metabolism of the cell and to a physiological effect of membrane depolarization caused by the carbohydrate metabolism
Data Source
Figure 1A
Figure 1B~1C
Figure 1D~1E
AI summary
The present invention relates to β-cell-mimetic cells. Methods for producing β-cell-mimetic cells as well as methods of use of β-cell-mimetic cells as a medicament and methods of use of β-cell-mimetic cells for the prevention, delay of progression or treatment of a metabolic disease in a subject are also provided.